Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 4,234,144 shares, a growth of 76.1% from the July 15th total of 2,404,454 shares. Based on an average trading volume of 52,873,116 shares, the days-to-cover ratio is presently 0.1 days. Currently, 10.4% of the company’s stock are sold short.

Liminatus Pharma Stock Up 4.3%

Shares of NASDAQ:LIMN traded up $0.01 during trading on Monday, reaching $0.15. 1,162,643 shares of the company traded hands, compared to its average volume of 20,955,160. The firm has a fifty day simple moving average of $0.12 and a 200 day simple moving average of $0.25. Liminatus Pharma has a 1-year low of $0.10 and a 1-year high of $4.12. The firm has a market cap of $7.39 million, a P/E ratio of -0.31 and a beta of 5.34.

Liminatus Pharma (NASDAQ:LIMN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.03) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.